Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain

Xavier Granero Xiberta; Antonio Murcia; José Ricardo Troncoso Durán; Claudio Gómez Zubeldia; Aleix Llorac Moix; Ruth Graefenhain De Codes; Maria Giovana Ferrario; Luis Lizán

doi:10.36469/9824

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

JHEOR

Articles
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers

search
X (formerly Twitter) (opens in a new tab)
Bluesky (opens in a new tab)
LinkedIn (opens in a new tab)
RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:37662/feed

ISSN 2327-2236

Cardiovascular Conditions

Vol. 4, Issue 1, 2016

January 28, 2016 EDT

Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain

Xavier Granero Xiberta, Antonio Murcia, José Ricardo Troncoso Durán, Claudio Gómez Zubeldia, Aleix Llorac Moix, Ruth Graefenhain De Codes, Maria Giovana Ferrario, Luis Lizán,

budget impactenoxaparinrivaroxabanmajor orthopedic surgerytotal knee replacementtotal hip replacementantithrombotic prophylaxis

ccby-4.0

• https://doi.org/10.36469/9824

Photo by Piron Guillaume on Unsplash

JHEOR

Granero Xiberta X, Murcia A, Troncoso Durán JR, et al. Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain. JHEOR. 2016;4(1):35-46. doi:10.36469/9824

View more stats